<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257230</url>
  </required_header>
  <id_info>
    <org_study_id>205.444</org_study_id>
    <secondary_id>2010-021093-11</secondary_id>
    <nct_id>NCT01257230</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma</brief_title>
  <official_title>A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety Over 48 Weeks of Orally Inhaled Tiotropium Bromide (2.5 and 5 µg Once Daily ) Delivered by the Respimat® Inhaler in Adolescents (12 to 17 Years Old) With Moderate Persistent Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate efficacy and safety of a 48-week treatment with two doses
      of tiotropium bromide compared to placebo in adolescent patients with moderate persistent
      asthma. Efficacy and safety will be assessed by measuring lung function parameters and
      evaluating the effects on asthma exacerbations, on Quality of life, on health care resource
      utilisation an on the number of adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 peak0-3 Change From Baseline</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Change from baseline in peak Forced expiratory volume in 1 second within the first 3 hours post dosing (FEV1 peak0-3) measured at week 24.
Note, the measured values presented are actually adjusted means.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Change From Baseline</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Change from baseline in Trough (pre-dose) Forced expiratory volume in 1 second (FEV1) measured at week 24.
The measured values presented are actually adjusted means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC peak0-3 Change From Baseline</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Change from baseline in Maximum forced vital capacity (FVC) measured within the first 3 h after administration of trial medication (FVC peak0-3h) after 24 weeks of treatment.
The measured values presented are actually adjusted means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Change From Baseline</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Change from baseline of Trough (pre-dose) forced vital capacity (FVC) measured 10 min before the administration of trial medication after 24 weeks of treatment.
The measured values presented are actually adjusted means..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC (0-3h) Change From Baseline</measure>
    <time_frame>Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 24 weeks</time_frame>
    <description>Change from baseline of area under the curve (AUC) from 0 to 3 h for FEV1 (FEV1 AUC 0-3h) after 24 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).
The measured values presented are actually adjusted means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC (0-3h) Change From Baseline</measure>
    <time_frame>Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 24 weeks</time_frame>
    <description>Change from baseline of area under the curve (AUC) from 0 to 3 h for FVC (FVC AUC0-3h) after 24 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).
The measured values presented are actually adjusted means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEF25-75 Change From Baseline</measure>
    <time_frame>Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 24 weeks</time_frame>
    <description>Change from baseline in mean forced expiratory flow between 25% and 75% of the FVC (FEF25-75%), also known as maximum mid-expiratory flow, at individual time points after 24 weeks of treatment.
The measured values presented are actually adjusted means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of PRN Rescue Medication During the Daytime</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the daytime based on the weekly mean at week 24.
The measured values presented are actually adjusted means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of PRN Rescue Medication During the Night-time</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the night-time based on the weekly mean at week 24.
The measured values presented are actually adjusted means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of PRN Rescue Medication During the Day</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the day (24 hour period) based on the weekly mean at week 24.
The measured values presented are actually adjusted means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control of Asthma as Assessed by ACQ Total Score</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>Change from baseline in Asthma Control Questionnaire (ACQ) total score measured at week 24.
The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment. ACQ total score was calculated as the mean of the responses to all 7 questions.
The measured values presented are actually adjusted means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACQ Total Score Responders</measure>
    <time_frame>Week 24</time_frame>
    <description>Responder rates based on the ACQ total score after 24 weeks of treatment. Analysis was performed using the following categories and definitions: responder (change from trial baseline ≤-0.5), no change (-0.5 &lt;change from trial baseline &lt;0.5) and worsening (change from trial baseline ≥0.5)
The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control of Asthma as Assessed by ACQ6</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>Change from baseline in AQC6 score at week 24.
The ACQ6 score is calculated as the mean of the responses to the first 6 questions of the ACQ. The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment.
The measured values presented are actually adjusted means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACQ6 Responders</measure>
    <time_frame>Week 24</time_frame>
    <description>Responder rates based on the ACQ6 after 24 weeks of treatment. Analysis was performed using the following categories and definitions: responder (change from trial baseline ≤-0.5), no change (-0.5 &lt;change from trial baseline &lt;0.5) and worsening (change from trial baseline ≥0.5)
The ACQ6 score is calculated as the mean of the responses to the first 6 questions of the ACQ. The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Severe Asthma Exacerbation During the 48 Week Treatment Period</measure>
    <time_frame>48 weeks</time_frame>
    <description>The median time to first severe asthma exacerbation was not calculable, so the number of patients who experienced a severe asthma exacerbation are presented for the measured values. A severe asthma exacerbation was defined as a subgroup of all asthma exacerbations that required treatment with systemic corticosteroid for at least 3 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Asthma Exacerbation During the 48 Week Treatment Period</measure>
    <time_frame>Week 48</time_frame>
    <description>The median time to first asthma exacerbation was not calculable, so the number of patients who experienced an asthma exacerbation are presented for the measured values.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">398</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once daily, delivered with Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily, delivered with Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily, delivered with Respimat inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium Respimat low dose</intervention_name>
    <description>IMP</description>
    <arm_group_label>tiotropium low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo Respimat</intervention_name>
    <description>placebo representing comparator</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium Respimat high dose</intervention_name>
    <description>IMP</description>
    <arm_group_label>tiotropium high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. All patients and their parents (or legally accepted caregiver) must sign and date an
             informed consent consistent with ICH-GCP guidelines and local legislation prior to
             participation in the trial.

          2. Male or female patients between 12 and 17 years of age.

          3. All patients must have at least a 3 months history of asthma at the time of enrolment
             into the trial. The diagnosis of asthma has to be confirmed at visit 1 with a
             bronchodilator reversibility test.

          4. All patients must have been on maintenance treatment with inhaled corticosteroids at a
             stable medium dose for at least 4 weeks before Visit 1.

          5. All patients must be symptomatic (partly controlled) at Visit 1 (screening) and at
             randomisation defined by an Asthma Control Questionnaire (ACQ) mean score of more than
             or equal to 1.5.

          6. All patients must have a pre-bronchodilator FEV1 more than or equal to 60% and less
             than or equal to 90% of predicted normal at Visit 1. Variation of absolute FEV1 values
             of Visit 1 as compared to Visit 2 must be within ± 30%.

          7. All patients must have an increase in FEV1 of equal or above 12% and 200 mL after 400
             µg salbutamol (albuterol) at Visit 1. If patients in the lower age range (e.g., 12 to
             14 year olds) exhibit a very small total lung volume, positive reversibility testing
             might be based solely on the relative (12%) post-bronchodilator response.

          8. All patients should be never-smokers or ex-smokers who stopped smoking at least one
             year prior to enrolment.

          9. Patients should be able to use the Respimat® inhaler correctly.

         10. Patients must be able to perform all trial related procedures including technically
             acceptable spirometric manoeuvres.

        Exclusion criteria:

          1. Patients with a significant disease other than asthma.

          2. Patients with clinically relevant abnormal screening haematology or blood chemistry

          3. Patients with a history of congenital or acquired heart disease, and/or have been
             hospitalised for cardiac syncope or failure during the past year.

          4. Patients with any unstable or life-threatening cardiac arrhythmia or cardiac
             arrhythmia requiring intervention or a change in drug therapy within the past year.

          5. Patients with malignancy for which the patient has undergone resection, radiation
             therapy or chemotherapy within the last five years.

          6. Patients with lung diseases other than asthma (e.g. Cystic Fibrosis). In case of
             ex-premature infants, a history of significant bronchopulmonary dysplasia will be
             regarded as exclusion criterion.

          7. Patients with known active tuberculosis.

          8. Patients with significant alcohol or drug abuse within the past two years.

          9. Patients who have undergone thoracotomy with pulmonary resection.

         10. Patients who are currently in a pulmonary rehabilitation program or have completed a
             pulmonary rehabilitation program in the 6 weeks prior to the screening visit (Visit
             1).

         11. Patients with known hypersensitivity to anticholinergic drugs, Benzalkonium chloride
             (BAC), Ethylenediaminetetraacetic acis (EDTA) or any other components of the
             tiotropium inhalation solution.

         12. Pregnant or nursing adolescent female patients

         13. Sexually active female patients of child-bearing potential not using a highly
             effective method of birth control.

         14. Patients who have taken an investigational drug within 4 weeks prior to Visit 1.

         15. Patients who have been treated with long-acting anticholinergics (e.g. tiotropium
             -Spiriva) within four weeks prior to screening (Visit 1).

         16. Patients who are unable to comply with pulmonary medication restrictions prior to
             randomisation.

         17. Patients who have been treated with Anti-IgE treatment (Omalizumab Xolair) within the
             last 6 months prior to screening.

         18. Patients who have been treated with systemic (oral or intravenous) corticosteroids
             within 4 weeks prior to screening (Visit 1).

         19. Patients who have been treated with long-acting theophylline preparations within 2
             weeks prior to screening (Visit 1) or during the run-in period

         20. Patients who have been treated with other non-approved and according to international
             guidelines not recommended ¿experimental¿ drugs for routine asthma therapy.

         21. Patients with any acute asthma exacerbation or respiratory tract infection in the 4
             weeks prior to Visit 1.

         22. Patients requiring 10 or more puffs of rescue medication (salbutamol/albuterol) per
             day on more than 2 consecutive days during the run-in period.

         23. Patients who have previously been randomised in this trial or are currently
             participating in another study.

         24. Patients who are being treated with oral beta-blocker medication.

         25. Patients with a known narrow-angle glaucoma, or any other disease where
             anticholinergic treatment is contraindicated.

         26. Patients with renal impairment, as defined by a creatinine clearance less than 50
             mL/min/1.73 m2 Body Surface Area as calculated by Schwartz formula.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>205.444.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.01005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.01014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.01012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.01013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.56002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.56001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Viña del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.56003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Viña del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ettenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rosenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.36007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ajka</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.36005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.36008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.36006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaposvar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mosdos</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szigetbecse</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guri</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.37101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baldone</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.37107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Balvi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.37102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ogre</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.37105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rezekne</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.37106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.37103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Talsi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.37104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tukums</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.52002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.52001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hermosillo</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.52003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.70003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.70002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.70004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.70005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.70006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.70001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.42104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.42106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.42101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.42105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roznava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.34007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Esplugues del Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Majadahonda (Madrid)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marbella</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sabdadell</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.34008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.38008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.38010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zaporizhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.444.38009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Norway</country>
  </removed_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <results_first_submitted>June 12, 2014</results_first_submitted>
  <results_first_submitted_qc>August 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2014</results_first_posted>
  <last_update_submitted>August 27, 2014</last_update_submitted>
  <last_update_submitted_qc>August 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Respimat</title>
          <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
        </group>
        <group group_id="P2">
          <title>Tio R2.5</title>
          <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
        </group>
        <group group_id="P3">
          <title>Tio R5</title>
          <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="125"/>
                <participants group_id="P3" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set which included all randomised patients who were dispensed trial medication and received at least one documented dose of trial medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Respimat</title>
          <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
        </group>
        <group group_id="B2">
          <title>Tio R2.5</title>
          <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
        </group>
        <group group_id="B3">
          <title>Tio R5</title>
          <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="138"/>
            <count group_id="B2" value="125"/>
            <count group_id="B3" value="134"/>
            <count group_id="B4" value="397"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.2" spread="1.7"/>
                    <measurement group_id="B2" value="14.2" spread="1.8"/>
                    <measurement group_id="B3" value="14.5" spread="1.6"/>
                    <measurement group_id="B4" value="14.3" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1 peak0-3 Change From Baseline</title>
        <description>Change from baseline in peak Forced expiratory volume in 1 second within the first 3 hours post dosing (FEV1 peak0-3) measured at week 24.
Note, the measured values presented are actually adjusted means.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Full analysis set (FAS) was the same as the treated set which included all randomised patients who were dispensed trial medication and received at least one documents dose of trial medication. Missing data at a visit was imputed by the available data from the patient at that visit, completely missing visits were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 peak0-3 Change From Baseline</title>
          <description>Change from baseline in peak Forced expiratory volume in 1 second within the first 3 hours post dosing (FEV1 peak0-3) measured at week 24.
Note, the measured values presented are actually adjusted means.</description>
          <population>Full analysis set (FAS) was the same as the treated set which included all randomised patients who were dispensed trial medication and received at least one documents dose of trial medication. Missing data at a visit was imputed by the available data from the patient at that visit, completely missing visits were handled by the statistical model.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.373" spread="0.037"/>
                    <measurement group_id="O2" value="0.507" spread="0.040"/>
                    <measurement group_id="O3" value="0.547" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0085</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.134</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.051</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.034</ci_lower_limit>
            <ci_upper_limit>0.234</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.174</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.076</ci_lower_limit>
            <ci_upper_limit>0.272</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Change From Baseline</title>
        <description>Change from baseline in Trough (pre-dose) Forced expiratory volume in 1 second (FEV1) measured at week 24.
The measured values presented are actually adjusted means.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Full analysis set. Missing data at a visit was imputed by the available data from the patient at that visit, completely missing visits were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Change From Baseline</title>
          <description>Change from baseline in Trough (pre-dose) Forced expiratory volume in 1 second (FEV1) measured at week 24.
The measured values presented are actually adjusted means.</description>
          <population>Full analysis set. Missing data at a visit was imputed by the available data from the patient at that visit, completely missing visits were handled by the statistical model.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.283" spread="0.040"/>
                    <measurement group_id="O2" value="0.367" spread="0.044"/>
                    <measurement group_id="O3" value="0.400" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1307</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.084</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.025</ci_lower_limit>
            <ci_upper_limit>0.194</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0320</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.117</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.054</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.010</ci_lower_limit>
            <ci_upper_limit>0.223</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC peak0-3 Change From Baseline</title>
        <description>Change from baseline in Maximum forced vital capacity (FVC) measured within the first 3 h after administration of trial medication (FVC peak0–3h) after 24 weeks of treatment.
The measured values presented are actually adjusted means.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Full analysis set. Missing data at a visit was imputed by the available data from the patient at that visit, completely missing visits were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>FVC peak0-3 Change From Baseline</title>
          <description>Change from baseline in Maximum forced vital capacity (FVC) measured within the first 3 h after administration of trial medication (FVC peak0–3h) after 24 weeks of treatment.
The measured values presented are actually adjusted means.</description>
          <population>Full analysis set. Missing data at a visit was imputed by the available data from the patient at that visit, completely missing visits were handled by the statistical model.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.331" spread="0.041"/>
                    <measurement group_id="O2" value="0.419" spread="0.045"/>
                    <measurement group_id="O3" value="0.403" spread="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1231</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.088</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.057</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.024</ci_lower_limit>
            <ci_upper_limit>0.200</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1950</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.072</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.037</ci_lower_limit>
            <ci_upper_limit>0.182</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Change From Baseline</title>
        <description>Change from baseline of Trough (pre-dose) forced vital capacity (FVC) measured 10 min before the administration of trial medication after 24 weeks of treatment.
The measured values presented are actually adjusted means..</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Full analysis set. Missing data at a visit was imputed by the available data from the patient at that visit, completely missing visits were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Change From Baseline</title>
          <description>Change from baseline of Trough (pre-dose) forced vital capacity (FVC) measured 10 min before the administration of trial medication after 24 weeks of treatment.
The measured values presented are actually adjusted means..</description>
          <population>Full analysis set. Missing data at a visit was imputed by the available data from the patient at that visit, completely missing visits were handled by the statistical model.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.281" spread="0.043"/>
                    <measurement group_id="O2" value="0.345" spread="0.047"/>
                    <measurement group_id="O3" value="0.316" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2921</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.063</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.060</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.055</ci_lower_limit>
            <ci_upper_limit>0.181</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5495</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.035</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.059</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.080</ci_lower_limit>
            <ci_upper_limit>0.150</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC (0-3h) Change From Baseline</title>
        <description>Change from baseline of area under the curve (AUC) from 0 to 3 h for FEV1 (FEV1 AUC 0–3h) after 24 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).
The measured values presented are actually adjusted means.</description>
        <time_frame>Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 24 weeks</time_frame>
        <population>Full analysis set. Missing data at a visit was imputed by the available data from the patient at that visit, completely missing visits were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC (0-3h) Change From Baseline</title>
          <description>Change from baseline of area under the curve (AUC) from 0 to 3 h for FEV1 (FEV1 AUC 0–3h) after 24 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).
The measured values presented are actually adjusted means.</description>
          <population>Full analysis set. Missing data at a visit was imputed by the available data from the patient at that visit, completely missing visits were handled by the statistical model.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.281" spread="0.035"/>
                    <measurement group_id="O2" value="0.411" spread="0.038"/>
                    <measurement group_id="O3" value="0.463" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0079</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.130</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.049</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.034</ci_lower_limit>
            <ci_upper_limit>0.225</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.181</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.088</ci_lower_limit>
            <ci_upper_limit>0.275</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC (0-3h) Change From Baseline</title>
        <description>Change from baseline of area under the curve (AUC) from 0 to 3 h for FVC (FVC AUC0–3h) after 24 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).
The measured values presented are actually adjusted means.</description>
        <time_frame>Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 24 weeks</time_frame>
        <population>Full analysis set. Missing data at a visit was imputed by the available data from the patient at that visit, completely missing visits were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC (0-3h) Change From Baseline</title>
          <description>Change from baseline of area under the curve (AUC) from 0 to 3 h for FVC (FVC AUC0–3h) after 24 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).
The measured values presented are actually adjusted means.</description>
          <population>Full analysis set. Missing data at a visit was imputed by the available data from the patient at that visit, completely missing visits were handled by the statistical model.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.240" spread="0.039"/>
                    <measurement group_id="O2" value="0.330" spread="0.042"/>
                    <measurement group_id="O3" value="0.311" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0945</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.090</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.054</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.016</ci_lower_limit>
            <ci_upper_limit>0.196</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1755</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.071</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.032</ci_lower_limit>
            <ci_upper_limit>0.175</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEF25-75 Change From Baseline</title>
        <description>Change from baseline in mean forced expiratory flow between 25% and 75% of the FVC (FEF25-75%), also known as maximum mid-expiratory flow, at individual time points after 24 weeks of treatment.
The measured values presented are actually adjusted means.</description>
        <time_frame>Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 24 weeks</time_frame>
        <population>Full analysis set. Missing data at a visit was imputed by the available data from the patient at that visit, completely missing visits were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>FEF25-75 Change From Baseline</title>
          <description>Change from baseline in mean forced expiratory flow between 25% and 75% of the FVC (FEF25-75%), also known as maximum mid-expiratory flow, at individual time points after 24 weeks of treatment.
The measured values presented are actually adjusted means.</description>
          <population>Full analysis set. Missing data at a visit was imputed by the available data from the patient at that visit, completely missing visits were handled by the statistical model.</population>
          <units>Litres per second</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 minutes pre-dose (n=137, 119, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.332" spread="0.072"/>
                    <measurement group_id="O2" value="0.461" spread="0.079"/>
                    <measurement group_id="O3" value="0.609" spread="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.372" spread="0.066"/>
                    <measurement group_id="O2" value="0.536" spread="0.072"/>
                    <measurement group_id="O3" value="0.763" spread="0.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.359" spread="0.067"/>
                    <measurement group_id="O2" value="0.596" spread="0.072"/>
                    <measurement group_id="O3" value="0.835" spread="0.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.403" spread="0.069"/>
                    <measurement group_id="O2" value="0.615" spread="0.075"/>
                    <measurement group_id="O3" value="0.857" spread="0.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.347" spread="0.068"/>
                    <measurement group_id="O2" value="0.653" spread="0.074"/>
                    <measurement group_id="O3" value="0.850" spread="0.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of PRN Rescue Medication During the Daytime</title>
        <description>Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the daytime based on the weekly mean at week 24.
The measured values presented are actually adjusted means.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Use of PRN Rescue Medication During the Daytime</title>
          <description>Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the daytime based on the weekly mean at week 24.
The measured values presented are actually adjusted means.</description>
          <population>FAS</population>
          <units>Number of puffs of rescue medication</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.206" spread="0.066"/>
                    <measurement group_id="O2" value="-0.209" spread="0.071"/>
                    <measurement group_id="O3" value="-0.215" spread="0.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9760</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.003</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.092</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.184</ci_lower_limit>
            <ci_upper_limit>0.178</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9224</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.009</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.090</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.186</ci_lower_limit>
            <ci_upper_limit>0.168</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of PRN Rescue Medication During the Night-time</title>
        <description>Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the night-time based on the weekly mean at week 24.
The measured values presented are actually adjusted means.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Use of PRN Rescue Medication During the Night-time</title>
          <description>Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the night-time based on the weekly mean at week 24.
The measured values presented are actually adjusted means.</description>
          <population>FAS</population>
          <units>Number of puffs of rescue medication</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.144" spread="0.059"/>
                    <measurement group_id="O2" value="-0.122" spread="0.064"/>
                    <measurement group_id="O3" value="-0.032" spread="0.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7852</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.023</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.083</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.140</ci_lower_limit>
            <ci_upper_limit>0.185</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1649</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.112</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.081</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.046</ci_lower_limit>
            <ci_upper_limit>0.271</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of PRN Rescue Medication During the Day</title>
        <description>Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the day (24 hour period) based on the weekly mean at week 24.
The measured values presented are actually adjusted means.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Use of PRN Rescue Medication During the Day</title>
          <description>Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during the day (24 hour period) based on the weekly mean at week 24.
The measured values presented are actually adjusted means.</description>
          <population>FAS</population>
          <units>Number of puffs of rescue medication</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.524" spread="0.098"/>
                    <measurement group_id="O2" value="-0.556" spread="0.104"/>
                    <measurement group_id="O3" value="-0.480" spread="0.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8253</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.032</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.143</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.312</ci_lower_limit>
            <ci_upper_limit>0.249</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7559</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.044</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.140</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.232</ci_lower_limit>
            <ci_upper_limit>0.319</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Control of Asthma as Assessed by ACQ Total Score</title>
        <description>Change from baseline in Asthma Control Questionnaire (ACQ) total score measured at week 24.
The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment. ACQ total score was calculated as the mean of the responses to all 7 questions.
The measured values presented are actually adjusted means.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Control of Asthma as Assessed by ACQ Total Score</title>
          <description>Change from baseline in Asthma Control Questionnaire (ACQ) total score measured at week 24.
The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment. ACQ total score was calculated as the mean of the responses to all 7 questions.
The measured values presented are actually adjusted means.</description>
          <population>FAS</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.213" spread="0.062"/>
                    <measurement group_id="O2" value="1.053" spread="0.067"/>
                    <measurement group_id="O3" value="1.116" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0653</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.160</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.087</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.330</ci_lower_limit>
            <ci_upper_limit>0.010</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2516</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.097</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.084</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.263</ci_lower_limit>
            <ci_upper_limit>0.069</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACQ Total Score Responders</title>
        <description>Responder rates based on the ACQ total score after 24 weeks of treatment. Analysis was performed using the following categories and definitions: responder (change from trial baseline ≤-0.5), no change (-0.5 &lt;change from trial baseline &lt;0.5) and worsening (change from trial baseline ≥0.5)
The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment.</description>
        <time_frame>Week 24</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>ACQ Total Score Responders</title>
          <description>Responder rates based on the ACQ total score after 24 weeks of treatment. Analysis was performed using the following categories and definitions: responder (change from trial baseline ≤-0.5), no change (-0.5 &lt;change from trial baseline &lt;0.5) and worsening (change from trial baseline ≥0.5)
The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment.</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="76.0"/>
                    <measurement group_id="O3" value="74.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5"/>
                    <measurement group_id="O2" value="21.6"/>
                    <measurement group_id="O3" value="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Control of Asthma as Assessed by ACQ6</title>
        <description>Change from baseline in AQC6 score at week 24.
The ACQ6 score is calculated as the mean of the responses to the first 6 questions of the ACQ. The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment.
The measured values presented are actually adjusted means.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Control of Asthma as Assessed by ACQ6</title>
          <description>Change from baseline in AQC6 score at week 24.
The ACQ6 score is calculated as the mean of the responses to the first 6 questions of the ACQ. The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment.
The measured values presented are actually adjusted means.</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.173" spread="0.068"/>
                    <measurement group_id="O2" value="1.026" spread="0.073"/>
                    <measurement group_id="O3" value="1.119" spread="0.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1200</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.147</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.095</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.333</ci_lower_limit>
            <ci_upper_limit>0.038</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5589</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.054</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.092</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.235</ci_lower_limit>
            <ci_upper_limit>0.127</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACQ6 Responders</title>
        <description>Responder rates based on the ACQ6 after 24 weeks of treatment. Analysis was performed using the following categories and definitions: responder (change from trial baseline ≤-0.5), no change (-0.5 &lt;change from trial baseline &lt;0.5) and worsening (change from trial baseline ≥0.5)
The ACQ6 score is calculated as the mean of the responses to the first 6 questions of the ACQ. The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment.</description>
        <time_frame>Week 24</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>ACQ6 Responders</title>
          <description>Responder rates based on the ACQ6 after 24 weeks of treatment. Analysis was performed using the following categories and definitions: responder (change from trial baseline ≤-0.5), no change (-0.5 &lt;change from trial baseline &lt;0.5) and worsening (change from trial baseline ≥0.5)
The ACQ6 score is calculated as the mean of the responses to the first 6 questions of the ACQ. The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment.</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6"/>
                    <measurement group_id="O2" value="76.8"/>
                    <measurement group_id="O3" value="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="3.2"/>
                    <measurement group_id="O3" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Severe Asthma Exacerbation During the 48 Week Treatment Period</title>
        <description>The median time to first severe asthma exacerbation was not calculable, so the number of patients who experienced a severe asthma exacerbation are presented for the measured values. A severe asthma exacerbation was defined as a subgroup of all asthma exacerbations that required treatment with systemic corticosteroid for at least 3 days.</description>
        <time_frame>48 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Severe Asthma Exacerbation During the 48 Week Treatment Period</title>
          <description>The median time to first severe asthma exacerbation was not calculable, so the number of patients who experienced a severe asthma exacerbation are presented for the measured values. A severe asthma exacerbation was defined as a subgroup of all asthma exacerbations that required treatment with systemic corticosteroid for at least 3 days.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4023</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0620</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Asthma Exacerbation During the 48 Week Treatment Period</title>
        <description>The median time to first asthma exacerbation was not calculable, so the number of patients who experienced an asthma exacerbation are presented for the measured values.</description>
        <time_frame>Week 48</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Asthma Exacerbation During the 48 Week Treatment Period</title>
          <description>The median time to first asthma exacerbation was not calculable, so the number of patients who experienced an asthma exacerbation are presented for the measured values.</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8700</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4198</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 30 days after last drug intake, up to 416 days</time_frame>
      <desc>Treated set which included all randomised patients who were dispensed trial medication and received at least one documented dose of trial medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Respimat</title>
          <description>Inhalation of placebo solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
        </group>
        <group group_id="E2">
          <title>Tio R2.5</title>
          <description>Inhalation of 2.5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
        </group>
        <group group_id="E3">
          <title>Tio R5</title>
          <description>Inhalation of 5μg tiotropium bromide solution once daily for 48 weeks, delivered by the Respimat Inhaler</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to plants</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Hepatic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Teratoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Peak expiratory flow rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

